Joy Bessenger
Director of Finance/CFO bei TRELLUS HEALTH PLC
Profil
Joy Bessenger is currently the Chief Financial Officer at Trellus Health Plc since 2023.
Prior to this, she worked as the Senior Vice President-Corporate Strategy at IMV, Inc. from 2021 to 2022.
Before that, she was the Director-Investor Relations at deCODE genetics, Inc. Ms. Bessenger completed her undergraduate degree at the University of South Florida.
Aktive Positionen von Joy Bessenger
| Unternehmen | Position | Beginn |
|---|---|---|
| TRELLUS HEALTH PLC | Director of Finance/CFO | 18.09.2023 |
Ehemalige bekannte Positionen von Joy Bessenger
| Unternehmen | Position | Ende |
|---|---|---|
| IMV INC. | Investor Relations Contact | 11.06.2022 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Public Communications Contact | - |
Ausbildung von Joy Bessenger
| University of South Florida | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IMV INC. | Health Technology |
| TRELLUS HEALTH PLC | Technology Services |
| Private Unternehmen | 1 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
